Drugs / HOT-1030
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05060263 | Mar 2021 → Jun 2023 | cancer | Huabo Biopharm Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HOT-1030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05060263 ↗ |
| Modality | Monoclonal antibody | “HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.” NCT05060263 ↗ |
| Route | Intravenous | “HOT-1030, every 21 days by intravenous administration.” NCT05060263 ↗ |